Skip to content
OpenCapital
Get started

Rigel Pharmaceuticals RIGL Discounts and allowances — Revenue recognized

Other product segments

Gross product sales
$75.39M+25.2%
Release Of Share Cost Liability
$39.98M—
Delivery of drug supplies, royalties and others
$3.9M-42.6%
Development Milestones
$0-100%

Similar metrics at other companies

Exelixis logo
EXELDiscounts and allowances — Total revenues
-$240.38M-15.3%
Alkermes logo
ALKSProduct Discounts — Accrued Sales Discounts Allowances And Reserves
$18.7M+21.8%
Geron logo
GERNSales returns and allowances — Total revenues
-$1.59M-1,308%
Madrigal Pharmaceuticals, Inc. logo
MDGLChargebacks, Discounts for Prompt Pay and Other Allowances — Provision related to sales in the current year
$37.82M+622%
Eli Lilly logo
LLYSales Rebates and Discounts
$17.55B+51.9%
Madrigal Pharmaceuticals, Inc. logo
MDGLChargebacks, Discounts for Prompt Pay and Other Allowances — Gross To Net Adjustments Reserve
$20.83M+363%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K—
Free cash flow-$22.0M—

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%—

Returns & leverage

See full
Return on equity174.1%—
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's discounts and allowances — revenue recognized.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's discounts and allowances — revenue recognized?
Rigel Pharmaceuticals (RIGL) reported discounts and allowances — revenue recognized of -$20.47M in Q1 2026.
How has Rigel Pharmaceuticals's discounts and allowances — revenue recognized changed year-over-year?
Rigel Pharmaceuticals's discounts and allowances — revenue recognized decreased by 23.0% year-over-year, from -$16.64M to -$20.47M.
What is the long-term trend for Rigel Pharmaceuticals's discounts and allowances — revenue recognized?
Over 4 years (2021 to 2025), Rigel Pharmaceuticals's discounts and allowances — revenue recognized has grown at a 43.9% compound annual growth rate (CAGR), from -$18.18M to -$77.98M.
What does discounts and allowances — revenue recognized mean?
This metric represents the total contra-revenue adjustments applied to gross product sales, including rebates, chargebacks, cash discounts, and returns. It reflects the financial impact of contractual obligations and market access agreements that reduce the net revenue realized from product sales. Monitoring this figure is essential for assessing the company's pricing power, the effectiveness of its commercial distribution strategy, and the underlying net realization rate of its pharmaceutical portfolio.